CTC1
Basic information
Region (hg38): 17:8224815-8248058
Previous symbols: [ "C17orf68" ]
Links
Phenotypes
GenCC
Source:
- cerebroretinal microangiopathy with calcifications and cysts 1 (Definitive), mode of inheritance: AR
- cerebroretinal microangiopathy with calcifications and cysts 1 (Strong), mode of inheritance: AR
- cerebroretinal microangiopathy with calcifications and cysts 1 (Strong), mode of inheritance: AR
- dyskeratosis congenita (Supportive), mode of inheritance: AD
- Coats plus syndrome (Supportive), mode of inheritance: AR
- cerebroretinal microangiopathy with calcifications and cysts 1 (Strong), mode of inheritance: AR
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Cerebroretinal microangiopathy with calcifications and cysts 1 | AR | General | Genetic knowledge may be beneficial related to issues such as selection of optimal supportive care, informed medical decision-making, prognostic considerations, and avoidance of unnecessary testing | Cardiovascular; Dermatologic; Hematologic; Musculoskeletal; Neurologic; Ophthalmologic | 3402627; 8628470; 15002047; 15079028; 16943371; 18076099; 21523908; 22267198; 22387016 |
ClinVar
This is a list of variants' phenotypes submitted to
- Dyskeratosis congenita (66 variants)
- not provided (13 variants)
- Cerebroretinal microangiopathy with calcifications and cysts 1 (13 variants)
- Coats plus syndrome (4 variants)
- CTC1-related disorder (2 variants)
- Inborn genetic diseases (2 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the CTC1 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 12 | 258 | 275 | |||
missense | 572 | 15 | 597 | |||
nonsense | 26 | 32 | ||||
start loss | 5 | |||||
frameshift | 39 | 13 | 56 | |||
inframe indel | 10 | |||||
splice donor/acceptor (+/-2bp) | 13 | 15 | ||||
splice region | 1 | 34 | 49 | 1 | 85 | |
non coding | 121 | 134 | 42 | 297 | ||
Total | 71 | 35 | 721 | 408 | 52 |
Highest pathogenic variant AF is 0.000355
Variants in CTC1
This is a list of pathogenic ClinVar variants found in the CTC1 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
17-8224925-C-G | Dyskeratosis congenita | Likely benign (Jan 12, 2018) | ||
17-8224949-T-C | Dyskeratosis congenita | Benign (Jan 12, 2018) | ||
17-8224982-C-A | not specified • Dyskeratosis congenita | Uncertain significance (Jan 12, 2018) | ||
17-8224994-C-T | Dyskeratosis congenita | Uncertain significance (Jan 12, 2018) | ||
17-8225101-G-A | Dyskeratosis congenita | Uncertain significance (Jan 12, 2018) | ||
17-8225254-C-G | Dyskeratosis congenita | Uncertain significance (Jan 13, 2018) | ||
17-8225332-T-G | Dyskeratosis congenita | Benign (Jan 13, 2018) | ||
17-8225338-C-T | Dyskeratosis congenita | Uncertain significance (Jan 13, 2018) | ||
17-8225396-C-T | Dyskeratosis congenita | Uncertain significance (Jan 12, 2018) | ||
17-8225455-A-T | Dyskeratosis congenita | Uncertain significance (Jan 13, 2018) | ||
17-8225495-G-A | Dyskeratosis congenita | Uncertain significance (Jan 12, 2018) | ||
17-8225644-G-A | Dyskeratosis congenita | Uncertain significance (Jan 13, 2018) | ||
17-8225650-C-T | Dyskeratosis congenita | Uncertain significance (Jan 13, 2018) | ||
17-8225682-C-T | Dyskeratosis congenita | Uncertain significance (Jan 13, 2018) | ||
17-8225755-A-G | Dyskeratosis congenita | Uncertain significance (Jan 13, 2018) | ||
17-8225808-AAT-A | Dyskeratosis Congenita, Recessive | Uncertain significance (Jun 14, 2016) | ||
17-8225827-T-C | Dyskeratosis congenita | Uncertain significance (Jan 12, 2018) | ||
17-8225842-A-G | Dyskeratosis congenita | Benign (Jan 13, 2018) | ||
17-8225843-C-T | Dyskeratosis congenita | Uncertain significance (Jan 13, 2018) | ||
17-8225884-A-T | Dyskeratosis congenita | Uncertain significance (Jan 13, 2018) | ||
17-8225938-C-T | Dyskeratosis congenita | Uncertain significance (Jan 13, 2018) | ||
17-8226034-C-T | Dyskeratosis congenita | Uncertain significance (Jan 13, 2018) | ||
17-8226065-G-C | Dyskeratosis congenita | Likely benign (Jan 12, 2018) | ||
17-8226074-C-A | Dyskeratosis congenita | Likely benign (Jan 13, 2018) | ||
17-8226090-C-T | Dyskeratosis congenita | Uncertain significance (Jan 13, 2018) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
CTC1 | protein_coding | protein_coding | ENST00000315684 | 23 | 21172 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
1.60e-11 | 1.00 | 124451 | 0 | 349 | 124800 | 0.00140 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 0.503 | 645 | 682 | 0.946 | 0.0000388 | 7726 |
Missense in Polyphen | 190 | 222.44 | 0.85417 | 2753 | ||
Synonymous | -0.0376 | 284 | 283 | 1.00 | 0.0000157 | 2613 |
Loss of Function | 3.97 | 29 | 63.0 | 0.461 | 0.00000327 | 673 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.00181 | 0.00181 |
Ashkenazi Jewish | 0.0000994 | 0.0000993 |
East Asian | 0.000835 | 0.000835 |
Finnish | 0.00427 | 0.00428 |
European (Non-Finnish) | 0.00135 | 0.00135 |
Middle Eastern | 0.000835 | 0.000835 |
South Asian | 0.000628 | 0.000621 |
Other | 0.00231 | 0.00231 |
dbNSFP
Source:
- Function
- FUNCTION: Component of the CST complex proposed to act as a specialized replication factor promoting DNA replication under conditions of replication stress or natural replication barriers such as the telomere duplex. The CST complex binds single-stranded DNA with high affinity in a sequence-independent manner, while isolated subunits bind DNA with low affinity by themselves. Initially the CST complex has been proposed to protect telomeres from DNA degradation (PubMed:19854130). However, the CST complex has been shown to be involved in several aspects of telomere replication. The CST complex inhibits telomerase and is involved in telomere length homeostasis; it is proposed to bind to newly telomerase-synthesized 3' overhangs and to terminate telomerase action implicating the association with the ACD:POT1 complex thus interfering with its telomerase stimulation activity. The CST complex is also proposed to be involved in fill-in synthesis of the telomeric C-strand probably implicating recruitment and activation of DNA polymerase alpha (PubMed:22763445). The CST complex facilitates recovery from many forms of exogenous DNA damage; seems to be involved in the re-initiation of DNA replication at repaired forks and/or dormant origins (PubMed:25483097). Involved in telomere maintenance (PubMed:19854131, PubMed:22863775). Involved in genome stability (PubMed:22863775). May be in involved in telomeric C-strand fill- in during late S/G2 phase (By similarity). {ECO:0000250|UniProtKB:Q5SUQ9, ECO:0000269|PubMed:19854130, ECO:0000269|PubMed:19854131, ECO:0000269|PubMed:22763445, ECO:0000269|PubMed:22863775, ECO:0000269|PubMed:25483097}.;
- Disease
- DISEASE: Cerebroretinal microangiopathy with calcifications and cysts 1 (CRMCC1) [MIM:612199]: An autosomal recessive pleiomorphic disorder characterized primarily by intracranial calcifications, leukodystrophy, and brain cysts, resulting in spasticity, ataxia, dystonia, seizures, and cognitive decline. Patients also have retinal telangiectasia and exudates (Coats disease) as well as extraneurologic manifestations, including osteopenia with poor bone healing and a high risk of gastrointestinal bleeding and portal hypertension caused by vasculature ectasias in the stomach, small intestine, and liver. Some individuals also have hair, skin, and nail changes, as well as anemia and thrombocytopenia. {ECO:0000269|PubMed:22267198, ECO:0000269|PubMed:22387016}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
Intolerance Scores
- loftool
- rvis_EVS
- -0.63
- rvis_percentile_EVS
- 16.81
Haploinsufficiency Scores
- pHI
- 0.128
- hipred
- N
- hipred_score
- 0.271
- ghis
- 0.533
Essentials
- essential_gene_CRISPR
- E
- essential_gene_CRISPR2
- E
- essential_gene_gene_trap
- E
- gene_indispensability_pred
- N
- gene_indispensability_score
- 0.114
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Ctc1
- Phenotype
- immune system phenotype; hematopoietic system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); homeostasis/metabolism phenotype; cellular phenotype; endocrine/exocrine gland phenotype; growth/size/body region phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan);
Gene ontology
- Biological process
- telomere maintenance;cellular response to DNA damage stimulus;regulation of G2/M transition of mitotic cell cycle;telomere maintenance via telomere lengthening;telomere capping;negative regulation of telomere maintenance via telomerase;multicellular organism growth;positive regulation of DNA replication;positive regulation of fibroblast proliferation;spleen development;thymus development;bone marrow development;hematopoietic stem cell proliferation;replicative senescence
- Cellular component
- nuclear chromosome, telomeric region;nucleus;CST complex
- Molecular function
- single-stranded DNA binding;protein binding;telomeric DNA binding;G-rich strand telomeric DNA binding